News Release 22-088
Inv. No(s). 337-TA-1417
Contact: Jennifer Andberg, 202-205-1819
The U.S. International Trade Commission (USITC) voted to institute an investigation of certain hydro dermabrasion systems and components thereof II. The products at issue in the investigation are described in the Commission’s notice of investigation.
The investigation is based on a complaint filed by HydraFacial LLC f/k/a Edge Systems LLC. of Long Beach, CA, on August 8, 2024, and supplemented on August23, 2024 and August 28, 2024. The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930 in the importation into the United States and sale of certain hydrodermabrasion systems and components thereof III that infringe patents asserted by the complainant. The complainants request that the USITC issue a limited exclusion order and cease and desist orders.
The USITC has identified the following respondents in this investigation:
- Luvo Medical Technologies Inc., Cambridge, Ontario, Canada,
- Clarion Medical Technologies, Inc., Cambridge, Ontario, Canada,
- Healthcare Markets, Inc. d/b/a Powered by MRP, Park City, Utah,
- Medical Purchasing Resource, LLC, Little Elm, TX,
- Bio-Infusions USA Inc., Seminole, FL,
- MIRAmedtech UG, Neulingen, Germany,
- eMIRAmed USA, LLC Irvine, CA, and
- MIRAmedtech SP. Z.O.O., Warsaw, Poland.
By instituting this investigation (337-TA-1417), the USITC has not yet made any decision on the merits of the case. The USITC’s Chief Administrative Law Judge will assign the case to one of the USITC’s administrative law judges (ALJ), who will schedule and hold an evidentiary hearing. The ALJ will make an initial determination as to whether there is a violation of section 337; that initial determination is subject to review by the Commission.
The USITC will make a final determination in the investigation at the earliest practicable time. Within 45 days after institution of the investigation, the USITC will set a target date for completing the investigation. USITC remedial orders in section 337 cases are effective when issued and become final 60 days after issuance unless disapproved for policy reasons by the U.S. Trade Representative within that 60-day period.